Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / May / Weighing Up Granulation Options
Manufacture Small Molecules Technology and Equipment Facilities & Equipment Technology & Manufacturing Sponsored

Weighing Up Granulation Options

Whether wet or dry, high shear or single pot, the best method is the one that matches your operational needs

By Andreas Znidar 05/04/2020 1 min read

Sponsored By

Share

Granulation is a long-standing process for tablet manufacturers – and a variety of technologies are available. But choosing the right system to fit your business needs is essential. What factors are the most important to your unit operations? Do you need the highest productivity, or will space constraints limit your choices?

First of all, do you need wet granulation or dry granulation? Wet granulation can be used to granulate a wide variety of products. It works by joining solid particles together using liquid solutions. The only major drawback to wet granulation is that, once granulated, particles must also be dried. And the drying process requires another piece of machinery or another process, depending on the technology. But, as the name suggests, the drying process can be avoided entirely using dry granulation, making it a more appropriate choice for products that are sensitive to moisture or heat. Dry granulation uses compacting rollers to produce a granular, free-flowing blend of uniform size. Though the process will work well for some products, it isn’t universally applicable as it requires special raw material properties. And that’s probably why wet granulation is the most popular approach.

There are several types of wet granulators, and companies should remember to consider the drying capabilities of each before making an investment decision.

High Shear. For contract manufacturers looking for a technology that meets the needs of a broad spectrum of customers, highshear granulation is a sensible option. With short processing times and the capacity to fully integrate upstream and downstream equipment, it is highly favored on an industrial scale, currently accounting for the granulation of roughly 70 percent of all wet-granulated products. The robustness of the technology allows it to function well with a variety of products. But high-shear granulation requires two specialized pieces of machinery – a High Shear Granulator and a Fluid Bed Dryer – and that means there is an increased risk of product loss and considerable cleaning effort to be taken into account.

Fluid Bed. Though less common than highshear granulation, fluid-bed granulation offers tremendous flexibility, as it allows particle size to be readily controlled by varying key process parameters, such as spray rate, droplet size, air volume and temperature. In fluid-bed technologies, the powder is fluidized by the air that is drawn up through it. Binder liquid is introduced into the chamber as droplets through a binary nozzle, which causes the powder material to form granules. The resulting granules are dried in the same process chamber, limiting product loss. Notably, the agglomerates produced by Fluid Bed Granulators have different particle properties compared with the granules produced by High Shear or Single Pot Granulators, with high porosity and hence low bulk density. Companies considering a change from High Shear to Fluid Bed Granulators must assess how the differences in granules will affect the hardness of the tablets they produce and determine whether a re-registration of their granulation process will be required. Moreover, process times are longer when compared with high-shear granulation.

Single Pot Processors. Using one piece of machinery for both mixing and drying, single-pot equipment is easier to clean than other granulation technologies. Single Pot Processors produce wet granulates that are dried under a vacuum, meaning that they are, by design, contained systems. For companies who need to make frequent product changes or work with toxic products, the combination of easy cleaning and containment is attractive. They are also a great option for companies working with effervescent products, which are extremely moisture-sensitive, because no additional moisture is introduced. Single Pot Processors also have the advantage of requiring less floor space for installation than granulation lines or Fluid Bed Granulators. 

Before moving to a new type of granulation processor, companies must always weigh up the advantages and disadvantages for their particular products and how they fit into the future needs of the business. If you are looking for a modern update to your processing systems, Diosna is on hand to offer the assistance you need – helping you make the transition from old-fashioned to contemporary with no headache.

Andreas Znidar is Area Sales Manager at Diosna.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Andreas Znidar

More Articles by Andreas Znidar

False

Advertisement

Recommended

False

Related Content

The Final Frontier?
Small Molecules
The Final Frontier?

December 1, 2014

0 min read

The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D

Calculate – Don’t Estimate – Drug Development Costs
Small Molecules
Calculate – Don’t Estimate – Drug Development Costs

December 1, 2014

0 min read

Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right? And how can we accurately determine the true costs?

Electrifying R&D Acceleration
Small Molecules Analytical Science
Electrifying R&D Acceleration

December 2, 2014

0 min read

Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings...

United Science Stands
Small Molecules Standards & Regulation
United Science Stands

December 2, 2014

0 min read

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.